"Infliximab" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A chimeric monoclonal antibody to TNF ALPHA that is used in the treatment of RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; PSORIATIC ARTHRITIS and CROHN'S DISEASE.
| Descriptor ID |
D000069285
|
| MeSH Number(s) |
D12.776.124.486.485.114.224.608 D12.776.124.790.651.114.224.537 D12.776.377.715.548.114.224.642
|
| Concept/Terms |
Infliximab- Infliximab
- MAb cA2
- Monoclonal Antibody cA2
- cA2, Monoclonal Antibody
|
Below are MeSH descriptors whose meaning is more general than "Infliximab".
Below are MeSH descriptors whose meaning is more specific than "Infliximab".
This graph shows the total number of publications written about "Infliximab" by people in this website by year, and whether "Infliximab" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 |
| 2002 | 0 | 2 | 2 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 2 | 2 |
| 2005 | 0 | 7 | 7 |
| 2006 | 0 | 5 | 5 |
| 2007 | 0 | 4 | 4 |
| 2008 | 0 | 5 | 5 |
| 2009 | 0 | 5 | 5 |
| 2010 | 0 | 3 | 3 |
| 2011 | 0 | 4 | 4 |
| 2013 | 0 | 4 | 4 |
| 2014 | 0 | 2 | 2 |
| 2015 | 0 | 1 | 1 |
| 2016 | 1 | 5 | 6 |
| 2017 | 2 | 4 | 6 |
| 2018 | 2 | 1 | 3 |
| 2019 | 2 | 1 | 3 |
| 2020 | 1 | 0 | 1 |
| 2021 | 2 | 2 | 4 |
| 2022 | 0 | 3 | 3 |
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Infliximab" by people in Profiles.
-
Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case series. J Immunother Cancer. 2024 01 31; 12(1).
-
Infliximab Rescue Therapy in Pediatric Severe Colitis. J Pediatr Surg. 2023 Oct; 58(10):1893-1897.
-
Infliximab Can Be Effective in Pediatric Patients with Ulcerative Colitis and Primary Failure of Adalimumab. Ann Clin Lab Sci. 2022 Sep; 52(5):796-801.
-
Re: Lin I, Melsheimer R, Bhak RH, et al. Impact of switching to infliximab biosimilars on treatment patterns among US veterans receiving innovator infliximab. Curr Med Res Opin. 2022;38(4):613-627. Curr Med Res Opin. 2022 12; 38(12):2241-2242.
-
Utilization of Antitumor Necrosis Factor Biologics in Very Early Onset Inflammatory Bowel Disease: A Multicenter Retrospective Cohort Study From North America. J Pediatr Gastroenterol Nutr. 2022 07 01; 75(1):64-69.
-
Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study. J Immunother Cancer. 2021 11; 9(11).
-
Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial. Lancet Child Adolesc Health. 2021 12; 5(12):852-861.
-
Therapeutic Drug Monitoring of Non-Anti-Tumor Necrosis Factor Biologics. Clin Gastroenterol Hepatol. 2021 06; 19(6):1108-1110.
-
Infliximab for the treatment of patients with checkpoint inhibitor-associated acute tubular interstitial nephritis. Oncoimmunology. 2021 02 02; 10(1):1877415.
-
A Remarkable Response of Granulomatous Hypophysitis to Infliximab in a Patient With a Background of Crohn's Disease-A Case Report. Front Endocrinol (Lausanne). 2020; 11:350.